Anticancer therapy

{
  "publication_number": "US9610371B2",
  "country": "US",
  "kind": "B2",
  "title": "Anticancer therapy",
  "abstract": "A subject afflicted with a cancer or precancerous condition is treated by administering an agent that increases expression of somatostatin receptors, and a cytotoxic recognition ligand. In an alternative embodiment, somatostatin analogs, which are radiolabeled are used to treat cancer or precancerous conditions.",
  "claims": [
    "1. A method of treating a somatostatin receptor expressing cancerous tumor in a patient in need, the method comprising administering to said patient an effective amount of a composition comprising a chelate-linked peptide analog of somatostatin comprising a radionuclide, wherein said peptide analog of somatostatin is Tyr 3 -Octreotide, said chelate is 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and said radionuclide is the α particle emitter 213 Bi (213 Bi-DOTATOC), in a pharmaceutically acceptable carrier, in combination with an additional anti-cancer compound, wherein said additional anti-cancer compound is Aldesleukin; Alemtuzumab; alitretinoin; allopurinol; altretamine; amifostine; anastrozole; arsenic trioxide; Asparaginase; BCG Live; bexarotene capsules; bexarotene gel; bleomycin; busulfan intravenous; busulfan oral; calusterone; capecitabine; carboplatin; carmustine; carmustine with Polifeprosan 20 Implant; celecoxib; chlorambucil; cisplatin; cladribine; cyclophosphamide; cytarabine; cytarabine liposomal; dacarbazine; dactinomycin, actinomycin D; Darbepoetin alfa; daunorubicin liposomal; daunorubicin, daunomycin; Denileukin diftitox, dexrazoxane; docetaxel; doxorubicin; doxorubicin liposomal; Dromostanolone propionate; Elliott's B Solution; epirubicin; Epoetin alfa estramustine; etoposide phosphate; etoposide (VP-16); exemestane; Filgrastim; floxuridine (intraarterial); fludarabine; fluorouracil (5-FU); fulvestrant; gemtuzumab ozogamicin; gleevec (imatinib); goserelin acetate; hydroxyurea; Ibritumomab Tiuxetan; idarubicin; ifosfamide; imatinib mesylate; Interferon alfa-2a; Interferon alfa-2b; irinotecan; letrozole; leucovorin; levamisole; lomustine (CCNU); meclorethamine (nitrogen mustard); megestrol acetate; melphalan (L-PAM); mercaptopurine (6-MP); mesna; methotrexate; methoxsalen; mitomycin C; mitotane; mitoxantrone; nandrolone phenpropionate; Nofetumomab; LOddC; Oprelvekin; oxaliplatin; paclitaxel; pamidronate; pegademase; Pegaspargase; Pegfilgrastim; pentostatin; pipobroman; plicamycin; mithramycin; porfimer sodium; procarbazine; quinacrine; Rasburicase; Rituximab; Sargramostim; streptozocin; surafenib; talbuvidine (LDT); talc; tamoxifen; tarceva (erlotinib); temozolomide; teniposide (VM-26); testolactone; thioguanine (6-TG); thiotepa; topotecan; toremifene; Tositumomab; Trastuzumab; tretinoinjATRA); Uracil Mustard; valrubicin; valtorcitabine (monoval LDC); vinblastine; vinorelbine; zoledronate; or a mixture thereof.",
    "2. The method according to claim 1 wherein said cancerous tumor is a cancer of the breast, pancreas, stomach, prostate, kidney, colon, rectal, thyroid, lung, kidney, liver, brain/central nervous system or lymph (malignant lymphoid cancer).",
    "3. The method according to claim 2 wherein said cancerous tumor is a cancer of the breast, pancreas, prostate or thyroid.",
    "4. The method according to claim 3 wherein said cancerous tumor is a cancer of the pancreas.",
    "5. The method according to claim 2 wherein said brain/central nervous system tumor is a meningioma, astrocytoma or glioma.",
    "6. A method of treating a somatostatin receptor expressing cancerous tumor in a patient in need, the method comprising administering to said patient an effective amount of a composition comprising a chelate-linked peptide analog of somatostatin comprising a radionuclide, wherein said peptide analog of somatostatin is Tyr 3 -Octreotide, said chelate is 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and said radionuclide is the α particle emitter 213 Bi (213 Bi-DOTATOC), in a pharmaceutically acceptable carrier, in combination with an additional anti-cancer compound, wherein said additional anti-cancer compound is gemcitabine, fluorouracil, irinotecan, oxaliplatin, paclitaxel, docetaxel, capecitabine or a mixture thereof.",
    "7. The method according to claim 6 wherein said cancerous tumor is a cancer of the breast, pancreas, stomach, prostate, kidney, colon, rectal, thyroid, lung, kidney, liver, brain/central nervous system or lymph (malignant lymphoid cancer)."
  ],
  "description_excerpt": "The invention was made with government support under Grant No. DE-FG01-001NE23554, awarded by the United States Department of Energy, and Grant No. DHHS/PHS/NIH/NCRR/GCRC, MO1 RR00997, awarded by the National Institutes of Health National Center for Research Resources. The U.S. Government has certain rights in this invention.\n\nSomatostatin is a 14-amino acid peptide hormone (somatostatin-14; SS-14) found in many cells, particularly those of neuroendocrine origin, that acts as a neurotransmitter in the central nervous system. Reubi et al., Cancer Res. 47, 5758-64 (1987). There is also a somatostatin variant released by β cells in the pancreatic islets that is a 28 amino acid peptide (somatostatin-28; SS-28). Somatostatin has an inhibitory effect on growth hormone, and a generally antiproliferative effect. Somatostatin receptors (SSTR or SSR) are found on the surface of human tumor cells, including cells with amine precursor uptake and decarboxylation properties, such as pituitary tumors, endocrine pancreatic tumors, carcinoids, paragangliomas, small cell lung cancers, medullary thyroid carcinomas and pheochromocytomas. Reubi et al., Metabolism, 41, 104-10 (1992); Patel, Front. Neuroendocrinol. 20, 157-98 (1999). Somatostatin receptors belong to the guanine nucleotide-binding regulatory protein (G-protein)-linked receptor family.\n\nSynthetic somatostatin analogs such as octreotide and lanreotide have been used for antitumor treatment and cancer detection. Jensen et al., J. Clin. Endocrinol. Metab., 85(10), 3507-8 (2000).",
  "cpc": [
    "A61K 51/08",
    "A61K 2300/00",
    "A61K 31/7068",
    "A61K 38/31",
    "A61K 45/06",
    "A61K 51/083",
    "A61K 51/088"
  ],
  "ipc": [
    "A61K 31/7068",
    "A61K 45/06",
    "A61K 51/08",
    "A61K 38/31",
    "A61K 51/00",
    "A61M 36/14"
  ],
  "assignees": [
    "STC UNM"
  ],
  "inventors": [
    "Jeffrey P. Norenberg"
  ],
  "filing_date": "2015-03-26",
  "publication_date": "2017-04-04",
  "grant_date": "2017-04-04",
  "priority_date": "2005-07-29",
  "application_number": "US-201514669313-A",
  "family_id": "37694512",
  "cited_by_count": 6,
  "citations": [
    "US5057302A",
    "US5428154A",
    "US4938949A",
    "US5214316A",
    "US5650134A",
    "US6077668A",
    "US5932189A",
    "US5597894A",
    "US6051554A",
    "US6930088B2",
    "US6358491B1",
    "US7202330B2",
    "US6316414B1",
    "US7122622B2",
    "US20040115203A1"
  ]
}